^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

Published date:
05/18/2023
Excerpt:
The most frequently mutated gene was TP53 in both groups followed by VHL in trastuzumab-sensitive patients and ATM in trastuzumab-resistant group...On the other hand, MLH1, SMARCB1, and SMO genes were only mutated in the resistant group....NGS sequencing is a useful tool to detect genetic variants that could predict response to trastuzumab therapy.
DOI:
10.1186/s40246-023-00493-5